XPA A23G polymorphism is associated with the elevated response to platinum-based chemotherapy in advanced non-small cell lung cancer  

作　　者：Jifeng Feng Xinchen Sun Ning Sun Shukui Qin Fan Li Hongyan Cheng Baoan Chen YuanDong Cao Jun Ma Lu Cheng Zuhong Lu Jiazhong Ji Yingfeng Zhou 

机构地区：[1]Medical School, Southeast University, Nanjing 210009, China [2]Jiangsu Cancer Hospital, Nanjing 210009, China [3]Zhongda Hospital, Southeast University, Nanjing 210009, China [4]Department of Oncology, The 81 th Hospital of PLA, Nanjing 210034, China [5]Laboratory of Molecular and Biomolecular Electronics, Southeast University, Nanjing 210096, China [6]Department of Oncology, Jiangbei People Hospital, Nanjing 210048, China

出　　处：《Acta Biochimica et Biophysica Sinica》2009年第5期429-435,共7页生物化学与生物物理学报（英文版）

摘　　要：DNA repair capacity （DRC） is correlated with sensitivity of cancer cells toward platinum-based chemotherapy. We hypothesize that genetic polymorphisms in DNA repair gene XPA （xeroderma pigmentosum group A） and XPG （xeroderma pigmentosum group G） （ERCC5, excision repair cross-complementation group 5）, which result in inter-individual differences in DNA repair efficiency, may predict clinical response to platinum agents in advanced non-small cell lung cancer （NSCLC） patients. In this study, we find that the A → G change of XPA A23G polymorphism significantly increased response to platinum-based chemotherapy. Polymorphism in XPG His46His was associated with a decreased treatment response, but was not statistically significant.DNA repair capacity （DRC） is correlated with sensitivity of cancer cells toward platinum-based chemotherapy. We hypothesize that genetic polymorphisms in DNA repair gene XPA （xeroderma pigmentosum group A） and XPG （xeroderma pigmentosum group G） （ERCC5, excision repair cross-complementation group 5）, which result in inter-individual differences in DNA repair efficiency, may predict clinical response to platinum agents in advanced non-small cell lung cancer （NSCLC） patients. In this study, we find that the A → G change of XPA A23G polymorphism significantly increased response to platinum-based chemotherapy. Polymorphism in XPG His46His was associated with a decreased treatment response, but was not statistically significant.

关 键 词：single nucleotide polymorphism GENECHIP XPA XPG nucleotide excision repair non-small cell lung cancer CHEMOTHERAPY 

分 类 号：Q346.5[生物学—遗传学] S852.43[农业科学—基础兽医学]